
Silvia Zibellini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3126717/publications.pdf Version: 2024-02-01



SILVIA ZIRFLLINI

#	Article	IF	CITATIONS
1	Clinical significance of somatic mutation in unexplained blood cytopenia. Blood, 2017, 129, 3371-3378.	1.4	379
2	Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms. Blood, 2013, 121, 2522-2528.	1.4	290
3	Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood, 2016, 128, 1408-1417.	1.4	249
4	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2016, 34, 3627-3637.	1.6	204
5	The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood, 2012, 119, 188-191.	1.4	150
6	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica, 2010, 95, 1792-1796.	3.5	91
7	Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica, 2017, 102, 2077-2085.	3.5	90
8	Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica, 2013, 98, 635-639.	3.5	75
9	Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica, 2011, 96, 454-458.	3.5	65
10	Relationship between clone metrics and clinical outcome in clonal cytopenia. Blood, 2021, 138, 965-976.	1.4	58
11	MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood, 2013, 122, 2284-2285.	1.4	56
12	CpG Oligonucleotide Combined with Interleukin-2 Reveals Unexpected Chromosomal Lesions In B-CLL. Blood, 2010, 116, 2411-2411.	1.4	44
13	Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients. Genes and Immunity, 2022, 23, 51-56.	4.1	41
14	Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. Leukemia and Lymphoma, 2013, 54, 2485-2489.	1.3	31
15	Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. Blood Cells, Molecules, and Diseases, 2009, 42, 286-291.	1.4	30
16	Ruxolitinib treatment and risk of B ell lymphomas in myeloproliferative neoplasms. American Journal of Hematology, 2019, 94, E185-E188.	4.1	26
17	Distinctive Clinical and Histological Features of Waldenström's Macroglobulinemia and Splenic Marginal Zone Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 103-105.	0.4	22
18	High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma. Human Pathology, 2009, 40, 1628-1637.	2.0	21

SILVIA ZIBELLINI

#	Article	IF	CITATIONS
19	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. British Journal of Haematology, 2010, 151, 435-439.	2.5	20
20	Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines?. Leukemia, 2012, 26, 1703-1707.	7.2	20
21	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. American Journal of Hematology, 2019, 94, 1193-1199.	4.1	18
22	MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation. Diagnostics, 2021, 11, 779.	2.6	14
23	A riskatstratification model based on the initial concentration of the serum monocional protein and <i><scp>MYD</scp>88</i> mutation status identifies a subset of patients with IgM monocional gammopathy of undetermined significance at high risk of progression to WaldenstrA¶m macroglobulinaemia or other lymphoproliferative disorders. British Journal of Haematology, 2019,	2.5	13
24	Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphaseâ€FISH. Hematological Oncology, 2013, 31, 136-142.	1.7	12
25	JAK inhibitors and risk of B-cell lymphomas. Blood, 2019, 133, 2251-2253.	1.4	12
26	High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories Blood, 2007, 110, 2620-2620.	1.4	8
27	Targeted nextâ€generation sequencing reveals molecular heterogeneity in nonâ€chronic lymphocytic leukemia clonal Bâ€cell lymphocytosis. Hematological Oncology, 2020, 38, 689-697.	1.7	7
28	Mutational and immunogenetic landscape of <scp>HCV</scp> â€associated Bâ€cell lymphoproliferative disorders. American Journal of Hematology, 2021, 96, E210-E214.	4.1	7
29	Chronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis. Leukemia Research Reports, 2015, 4, 45-46.	0.4	6
30	Somatic Mutations of ASXL1, RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia. Blood, 2014, 124, 1915-1915.	1.4	6
31	HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia. Leukemia and Lymphoma, 2007, 48, 805-807.	1.3	5
32	CLLU1 expression distinguishes chronic lymphocytic leukemia from other mature B-cell neoplasms. Leukemia Research, 2012, 36, 1204-1207.	0.8	4
33	An Insidious Presentation of Splenic Marginal Zone Lymphoma. Clinical Lymphoma and Myeloma, 2007, 7, 432-433.	1.4	3
34	Development of a Richter syndrome with a monoclonal component from a true B-cell chronic lymphocytic leukemia (B-CLL) treated with fludarabine. Annals of Hematology, 2007, 86, 619-622.	1.8	3
35	IGHV Unmutated Status Influences Outcome More Than IGHV1-69 Gene Usage Per Se in Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma and Myeloma, 2009, 9, 390-393.	1.4	3
36	Enrichment of Double RUNX1 Mutations in Acute Leukemias of Ambiguous Lineage. Frontiers in Oncology, 2021, 11, 726637.	2.8	3

SILVIA ZIBELLINI

#	Article	IF	CITATIONS
37	Targeted Next Generation Sequencing Identifies Novel Genetic Mutations in Patients with Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma or IgM-Monoclonal Gammopathies of Undetermined Significance. Blood, 2016, 128, 2928-2928.	1.4	2
38	Biological markers and prognostic scoring systems in chronic lymphocytic leukaemia. British Journal of Haematology, 2009, 147, 402-404.	2.5	1
39	Splenic Marginal Zone B-Cell Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain Repertoires Blood, 2008, 112, 1775-1775.	1.4	1
40	The BRAF V600E Mutation in Hairy Cell Leukemia and Other Mature B-Cell Neoplasms. Blood, 2011, 118, 262-262.	1.4	1
41	Somatic Mutations Are Frequently Detected in Chronic Myeloid Leukemia in Chronic Phase and Do Not Affect Response to Tyrosine-Kinase Inhibitors. Blood, 2016, 128, 1117-1117.	1.4	1
42	Prevalence and Clinical Significance of the MYD88 (L265P) Somatic Mutation in Patients with Waldenstrol^m Macroglobulinemia, IgM-Monoclonal Gammopathy of Undetermined Significance or Other Mature B-Cell Neoplasms Blood, 2012, 120, 2667-2667.	1.4	1
43	Systemic mastocytosis and lymphoplasmacytic lymphoma: an unusual and intriguing form of SM-AHN. Leukemia and Lymphoma, 2021, 62, 1782-1785.	1.3	0
44	Evolution of a True B-Cell Chronic Lymphocytic Leukaemia (B-CLL) in a Diffuse Immunocytoma after Treatment with Fludarabine Blood, 2005, 106, 4973-4973.	1.4	0
45	Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome Blood, 2009, 114, 760-760.	1.4	0
46	Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia Blood, 2012, 120, 2657-2657.	1.4	0
47	Incidence and Clinical Significance of SF3B1 Somatic Mutation in Chronic Lymphocytic Leukemia Blood, 2012, 120, 2881-2881.	1.4	0
48	Hierarchical Clustering of B-Cell Receptor Structures in Splenic Marginal Zone Lymphoma. Blood, 2012, 120, 1585-1585.	1.4	0
49	Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials. Blood, 2015, 126, 5084-5084.	1.4	0
50	Driver Somatic Mutations and Transplantation Decision Making in Patients with Myelodysplastic Syndrome. Blood, 2016, 128, 53-53.	1.4	0
51	Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms. EJHaem, 0, , .	1.0	0